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frequently associated with self-induced
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ABSTRACT
Objective: To delineate the phenotype of early childhood epileptic encephalopathy due to de novo
mutations of CHD2, which encodes the chromodomain helicase DNA binding protein 2.
Methods: We analyzed the medical history, MRI, and video-EEG recordings of 9 individuals with
de novo CHD2 mutations and one with a de novo 15q26 deletion encompassing CHD2.
Results: Seizures began at a mean of 26 months (12–42) with myoclonic seizures in all 10 cases.
Seven exhibited exquisite clinical photosensitivity; 6 self-induced with the television.
Absence seizures occurred in 9 patients including typical (4), atypical (2), and absence seizures
with eyelid myoclonias (4). Generalized tonic-clonic seizures occurred in 9 of 10 cases with a
mean onset of 5.8 years. Convulsive and nonconvulsive status epilepticus were later features
(6/10, mean onset 9 years). Tonic (40%) and atonic (30%) seizures also occurred. In 3 cases, an
unusual seizure type, the atonic-myoclonic-absence was captured on video. A phenotypic
spectrum was identified with 7 cases having moderate to severe intellectual disability and refrac-
tory seizures including tonic attacks. Their mean age at onset was 23 months. Three cases had a
later age at onset (34 months) with relative preservation of intellect and an initial response to
antiepileptic medication.
Conclusion: The phenotypic spectrum of CHD2 encephalopathy has distinctive features of
myoclonic epilepsy, marked clinical photosensitivity, atonic-myoclonic-absence, and intellectual
disability ranging from mild to severe. Recognition of this genetic entity will permit earlier diag-
nosis and enable the development of targeted therapies. Neurology® 2015;84:951–958
GLOSSARY
ASD 5 autism spectrum disorder; CHD2 5 chromodomain helicase DNA binding protein 2; GSW 5 generalized spike wave;
MAE 5 epilepsy with myoclonic-atonic seizures.
The epileptic encephalopathies are severe epilepsy syndromes characterized by multiple seizure
types and developmental slowing, often associated with regression; many begin in infancy or
childhood. The etiology of these disorders is increasingly being recognized as due to de novo
genetic mutations with a recent explosion in the number of causative genes identified.1,2
In a cohort of 500 patients, targeted massively parallel sequencing identified de novo CHD2
mutations as the cause of 6 (1.2%) cases of epileptic encephalopathy and was the fourth most
frequently mutated gene after SCN1A, CDKL5, and STXBP1.1 Two of the 6 patients had been
diagnosed with epilepsy with myoclonic-atonic seizures (MAE) but their detailed phenotype was
not reported; one had Lennox-Gastaut syndrome with prominent photosensitivity and 3 had
nonspecific epileptic encephalopathies. In a later report,3 3 patients with de novo CHD2
mutations had an epileptic encephalopathy with fever sensitivity. CHD2 encodes the
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chromodomain helicase DNA binding protein
2, which likely alters gene expression via chro-
matin modification. We present the pheno-
type of CHD2 encephalopathy in 10 patients
including 3 novel cases, further analysis of our
6 published cases, and a case with a 15q26
deletion encompassing several genes including
CHD2.4
METHODS Nine cases were recruited to the Epilepsy Genetics
Research Program at the University of Melbourne. They formed
part of a large study of patients with epileptic encephalopathies
and were identified through genetic testing.1 Eight had CHD2
mutations identified via targeted next-generation sequencing of
candidate genes for epileptic encephalopathies.1 Our ninth case
harbored a de novo 15q26 deletion including CHD2 (chr15:
91,027,533–93,477,874 [hg19]; 2.4 Mb).4 This case was
included because the phenotype closely matched our other
cases with CHD2 encephalopathy. The tenth case was
ascertained via whole-exome sequencing of the proband and his
parents by the EuroEPINOMICS-RES Consortium. De novo
status was confirmed through parental sequencing of CHD2 in
all cases. We reviewed the medical history, video, and EEG
recordings of 10 individuals with CHD2 encephalopathy.
Where possible, we reviewed their inpatient video-EEG
monitoring records.
Estimates of intellectual disability were made from psycho-
metric testing and educational assessments when available.
Autism spectrum disorder (ASD) was diagnosed by a develop-
mental pediatrician. EEG with photic stimulation was performed
using the Grass PS33 plus stroboscope. Studies typically included
a superimposed pattern protocol together with a protocol in
which photic stimulation frequencies were repeated.
Standard protocol approvals, registrations, and patient
consents. The participants’ parents provided informed consent
for participation in the research study. The Austin Health
Human Research Ethics Committee approved the study.
RESULTS Seizures. The 10 patients had a mean age of
17.9 years (range 6–36 years) with a mean age at sei-
zure onset of 26 months (10–42 months); 6 were boys
(table e-1 on the Neurology® Web site at Neurology.
org). Seven cases presented with daily myoclonic
seizures, 4 of whom also had absence seizures at
onset. Seizure onset was explosive in 6 individuals
with multiple daily myoclonic and absence seizures.
All patients developed multiple seizure types. Myo-
clonic seizures occurred in all and were symmetric,
involving the upper limbs. Myoclonus was both spon-
taneous and triggered by environmental photic stimuli
in 6. A seventh case self-induced generalized tonic-
clonic seizures with the television; other reflex seizures
were not seen. Absence seizures occurred in 9 cases,
including typical (4), atypical absence (2), and eyelid
myoclonia with absence (4). Prolonged absence seiz-
ures and focal dyscognitive seizures were not observed.
The pattern evolved with the development of
tonic seizures in 4 patients at a mean of 3.6 years,
typically nocturnal, and atonic seizures in 3 at a mean
of 4.5 years. Generalized tonic-clonic seizures were a
later feature, present in 9 patients with a mean onset
of 5.8 years. The pattern of generalized tonic-clonic
seizures and tonic seizures changed from seizures at
any time to predominantly from sleep after 8 years.
Convulsive status epilepticus began at a mean of
9.7 years in 3, and nonconvulsive status in 5 at mean
9.2 years. Nonconvulsive status epilepticus often
included prominent myoclonic components. Fever
was not a prominent trigger; only one boy had febrile
seizures at 2 years.
The waking interictal EEG showed mild diffuse
background slowing at seizure onset in 7 patients.
The degree of slowing did not correlate with the
degree of intellectual disability.
Bursts of generalized spike wave (GSW) and gen-
eralized polyspike wave were frequently seen awake
and often markedly increased in sleep. GSW was
often slow at a frequency of 2 to 2.5 Hz (range 1–5
Hz) with a frontal predominance. The GSW was
brought out by eye closure in 3 patients.
Cases 1, 3, and 4 (at 20, 13, and 6 years, respec-
tively) progressed to abundant, almost continuous
slow spike wave that activated in sleep. Cases 1, 2,
and 8 exhibited interictal multifocal epileptiform
activity (table e-1).
Atonic-myoclonic-absence seizure. An unusual seizure
type was observed in 3 patients (cases 3, 4, 5) on home
videos and had a mean onset of 22 months (table e-1,
figure 1, videos 1–5). These seizures commenced with
an atonic component causing an abrupt head nod or
atonic fall with simultaneous eye elevation. The pa-
tients sometimes sustained injuries with the sudden
loss of tone. The seizure progressed to a myoclonic
absence phase characterized by ratchet-like tonic
abduction of the upper limbs; myoclonic activity
began while truncal atonia was still present. Seizures
were brief, lasting 2 to 8 seconds, with rapid return of
awareness.We termed this distinctive seizure type as an
“atonic-myoclonic-absence seizure.”
The ictal EEG showed paroxysms of 3- to 4-Hz
GSW and generalized polyspike wave activity
(figure 1). The atonic component of the atonic-
myoclonic-absence seizure correlated with the after-
going slow wave of the initial GSW discharge, and
each myoclonic jerk corresponded with the spike of
the spike wave complex (figure 1).
This seizure type was noted only in children aged
2 to 7 years and captured on home video. Patient 5
also had seizures recorded at 14 and 18 years that
resembled typical myoclonic absence seizures without
the preceding atonic component (videos 6 and 7).
Photosensitivity. Seven of 10 patients exhibited extreme
clinical photosensitivity with atonic myoclonic absence
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or absence seizures with eyelid myoclonia (table e-1).
Six patients were compelled to self-induce these
seizures by placing their face adjacent to the
television screen and had to be restrained from this
activity (video 5). In addition, case 1 had seizures
induced by the repetitive flash of a digital camera
as an infant. In contrast to the striking clinical
history of photosensitivity, only one case (8) had
a recorded photoparoxysmal response on EEG.
This comprised a grade 4 response showing GSW
across all frequencies. No cases demonstrated head
turning toward a light stimulus or “hand-flapping”
in sunlight to induce seizures.
Developmental course and behavioral features. Develop-
ment was normal in the first year of life in all 10 pa-
tients. All patients walked by 18 months. Speech
delay became evident between 1 and 2 years and pre-
ceded seizure onset (table 1). Seven had moderate to
severe intellectual disability and 3 had mild impair-
ment (table e-1, figure 2). Six of the 7 more-severe
cases had a history of regression that correlated
temporally with the explosive onset of seizures. In
general, regression tended to occur during periods
of seizure exacerbation. At the milder end, case 8
was succeeding in mainstream schooling until he
first regressed at age 9 years with seizure recurrence;
Figure 1 EEG of atonic-myoclonic-absence seizure
(A) Case 4, aged 14 years. Bipolar montage; (B) Case 5, aged 5.5 years. Bipolar montage. Ictal recordings show a parox-
ysm of 3 Hz generalized polyspike wave activity. The seizure begins with the head dropping forward or backward fol-
lowed by bilateral myoclonic ratcheting abduction of the upper limbs. The jerks correlate with the spike of the spike
wave complex.
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multiple seizures occurred and proved refractory to
treatment. Case 9 had speech regression at 24
months.
Four patients had a formal diagnosis of ASD in
addition to their intellectual disability. One also had
attention deficit hyperactivity disorder as did 2
without ASD. Challenging behavior was reported
in 8 patients and was independent of the degree
of intellectual disability. It primarily involved
aggressive behavior, and required risperidone in 3
cases. In addition, patient 10 developed a promi-
nent psychotic illness at 19 years requiring hospital-
ization and quetiapine.
Five individuals have reached adulthood. They
showed a broad spectrum of disability, with case
1 (31 years) at the severe end of the spectrum being
fully dependent on others for support, whereas case
9 (35 years) had the second mildest outcome in our
series. She lived at home with her family and never
worked but sang in a choir for “disadvantaged”
people.
Four individuals had short stature (less than
third centile) and the 2 most severe cases had head
circumferences less than third centile (table e-1) but
there were no consistent dysmorphic features. Neu-
rologic examination was normal. Five patients had a
crouch gait and 4 had ataxia. At 5 years, case 3 ex-
hibited chorea with facial dyskinesia and ataxia that
improved after the withdrawal of sodium valproate.
While case 5 at 9 years had ataxia and vomiting
associated with valproate, ataxia in case 8 from
age 13 years was independent of the withdrawal
and reintroduction of sodium valproate.
Seizures remained refractory to treatment in 7 of
10 cases; 3 cases, before the age of 10 years, had a
period of seizure control of more than a year’s dura-
tion. Three individuals trialled the ketogenic diet,
which did not produce significant benefit.
Neuroimaging.MRI brain studies were reviewed in 7
cases and showed progressive atrophy in 3 of 4 in-
dividuals with sequential studies (figure 3, table
e-1). Parenchymal atrophy was most marked poste-
riorly and associated with atrophy of the splenium
of the corpus callosum and mild diffuse cerebellar
atrophy in 3 cases (figure 3). Case 8 had a combi-
nation of callosal truncation (presumably develop-
mental) and progressive atrophy. Two of the 4 cases
with ataxia had cerebellar atrophy on MRI. Gener-
alized atrophy correlated to some extent with the
degree of intellectual disability as the 2 mildest cases
(9 and 10) had normal MRI scans in adult life.
White matter maturation was age-appropriate and
hippocampal sclerosis was not seen.
Molecular results. Our cohort included 3 new cases
with novel mutations, 6 from our previous
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publication identifying the role of CHD2 in epileptic
encephalopathies,1 and one from our study of copy
number variants.4 All cases have de novo mutations.
Seven had mutations resulting in premature trunca-
tion, 2 had missense mutations, and case 9 had a 2.4-
Mb deletion that included the 59 end of CHD2
resulting in a partial gene deletion.3 The phenotype
of this patient was consistent with CHD2
encephalopathy. The location of the mutations is
shown in figure 4.
DISCUSSION With the recent explosion in gene dis-
covery, an increasing number of novel genetic epileptic
encephalopathies are being recognized. In contrast to
Dravet syndrome in which the electroclinical pheno-
type was described well before the genetic finding of
SCN1A mutations, we are now in a position to delin-
eate the electroclinical phenotype of patients who share
the same genetic cause. The power of massively parallel
sequencing to rapidly and inexpensively screen panels
of known genes1 makes possible the recognition of
novel electroclinical syndromes through deep pheno-
typic analysis following gene identification.
CHD2 encephalopathy begins in the second year
of life and is characterized by myoclonic, absence, and
generalized tonic-clonic seizures and clinical photo-
sensitivity. We distinguished a spectrum of severity in
terms of age at onset, epilepsy severity, and cognitive
outcome (figure 2). Microcephaly occurred in only
the 2 most severe cases. Mean seizure onset in our
10 cases was 26 months with the more severe end of
the spectrum (7 cases) having a mean onset of 23
months vs 34 months at the milder end (3 cases)
(figure 2). CHD2 encephalopathy is associated with
refractory epilepsy but, in the milder cases, a period of
seizure freedom of more than a year may occur. The
hallmark of CHD2 encephalopathy, self-induced
photic seizures with the television, was common
across the spectrum.
The severe phenotype was characterized by mod-
erate to severe intellectual disability and tonic seiz-
ures. A similar pattern is described in other epileptic
Figure 2 CHD2 encephalopathy spectrum
CHD2 encephalopathy presents with a spectrum of severity including age of seizure onset, intellectual outcome, and seizure types. Cases are ranked by
their level of intellectual disability and age at onset. All cases had myoclonic seizures and 7 had photic-induced seizures. Cases with a milder intellectual
disability had fewer seizure types and were less likely to have atonic seizures, tonic seizures, and convulsive status epilepticus. Photic seizures were equally
likely across the spectrum. *A-M-A is likely to be underrecognized. AA 5 atypical absence; Abs 5 all absence seizure types; A-M-A 5 atonic-myoclonic-
absence seizure; CSE 5 convulsive status epilepticus; EMA 5 absence with eyelid myoclonia; GTCS 5 generalized tonic-clonic seizures; MS 5 myoclonic
seizures; NCSE 5 nonconvulsive status epilepticus; TA 5 typical absence.
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encephalopathies such as MAE in which the severe
cases develop tonic seizures.5
We identified an unusual seizure type beginning
with atonia and followed by myoclonic absence
(videos 1–5, figure 1), which we coined an atonic-
myoclonic-absence seizure. It is unclear whether this
seizure type occurs in all cases as we first recognized it
through home videotapes in a few cases. It may be an
age-dependent seizure type and therefore only record-
able for a limited time. It is of interest that these
appear to have the inverse sequence of classic
myoclonic-atonic seizures whereby a single myoclonic
jerk heralds the onset of the seizure followed by ato-
nia.6 Patient 8 had a history of seizures that was sus-
picious of the atonic-myoclonic-absence seizure type
at age 2.5 years, but video was not captured.
Confirmation of this seizure type using video-EEG
with EMG is required to determine whether it is sen-
sitive and specific for CHD2 encephalopathy.
How were these patients previously conceptual-
ized regarding their epilepsy syndrome? While 4 cases
were thought to have severe genetic (formerly idio-
pathic) generalized epilepsies, 3 had been previously
diagnosed with MAE,1 described by Doose et al.7
This was partly because of their prominent drop at-
tacks and the explosive onset of multiple seizure types
associated with GSW. While these epilepsies share
many features, there are elements that distinguish
them (table 1). First and foremost, the CHD2
encephalopathy cases do not have the archetypal sei-
zure that defines the syndrome of MAE, the
myoclonic-atonic seizure. In contrast to MAE,
CHD2 encephalopathy has the following features:
(1) development is usually delayed before seizure
onset; (2) seizure remission may occur in milder cases;
and (3) clinical photosensitivity is seen in the majority
of cases compared with less than a third of patients
with MAE.8 It was surprising that only one patient
showed electrical photosensitivity despite the marked
clinical photosensitivity in 7 cases and self-induction
with television screens seen in 6 patients.
CHD2 encephalopathy can be readily distin-
guished from Dravet syndrome by its later mean sei-
zure onset of 26 months compared with 6 months, its
high frequency of clinical photosensitivity compared
with ,50%, and the archetypal feature of self-
induced seizures, which is much rarer in Dravet syn-
drome (table 1).9,10 The paucity of febrile seizures and
abnormal development before seizure onset are also
key features that separate CHD2 encephalopathy
from Dravet syndrome.
Three patients have been recently described with
de novo mutations who had mild intellectual disabil-
ity, epileptic encephalopathy, and a predilection to
seizures with fever (table 1, figure 4).3 Clinical pho-
tosensitivity was not noted. One case had ASD and 2
had ataxia, one of whom showed atrophy on MRI in
keeping with our findings. We observed a more pos-
terior pattern of atrophy involving the parenchyma
and corpus callosum with additional cerebellar
involvement in those cases with ataxia.
Our findings are consistent with the previous case
reports in the literature of copy number variants
incorporating CHD2 and intragenic CHD2 muta-
tions (figure 4). The most similar phenotype of pho-
tosensitive myoclonic encephalopathy was reported in
a girl with a large 5-Mb deletion that included 56
genes.11 Among her seizure types was “massive myo-
clonias with head drop associated with irregular spike
and slow waves,”11 reminiscent of the atonic-
myoclonic-absence seizure. MRI demonstrated cere-
bellar hypoplasia with thinning of the posterior body
Figure 3 MRI of CHD2 encephalopathy
MRIs demonstrating progressive posterior atrophy. (A, B) Case 8 sagittal T1 MRIs at 10 years
(A) and sagittal T1 at 11 years (B) demonstrate a truncated, hypoplastic corpus callosum with
progressive atrophy and an atrophic cerebellar vermis. (C, D) Case 3 axial T2 at 2 years (C) and
T1 sagittal at 7 years (D) demonstrate generalized atrophy more marked posteriorly and
atrophic cerebellar vermis. The callosal atrophy is alsomore pronounced posteriorly. (E, F) Case
6 sagittal T1 (E) and axial T2 (F) at 12 years demonstrate generalized atrophy more prominent
posteriorly.
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of the corpus callosum. She had multiple dysmorphic
features that were not evident in our cases and may
relate to deletion of other genes. An earlier onset of
seizures at 6 months was noted in the single case with
a de novo splice site mutation from the EPI4K
study.11 A de novo CHD2 mutation has also been
reported in a child with intellectual disability and
absence epilepsy (T604Lfs*19)12 and another case
with ASD alone (D856G).13
Case 9 had a chromosome 15q26microdeletion that
results in partial deletion of CHD2.Her phenotype was
consistent with CHD2 encephalopathy but, remark-
ably, given the number of contiguous genes deleted,
was at the mild end of theCHD2 phenotypic spectrum.
Of the 5 published cases with deletions of varying size
that encompass CHD2, all had seizures and 4 had de-
layed development before seizure onset at 6 to 48
months. Intellectual disability was mild to severe.11,14–17
The missense, nonsense, frameshift, and splice site
mutations in CHD2 encephalopathy do not cluster in
any definite pattern within the gene (figure 4), and
the location or type of mutation does not correlate
with disease severity. CHD2 is among the genes that
are most intolerant to functional variation (ranked in
top 2.5%).18 In keeping with this, all functional var-
iation in the exome variant server are missense
changes, and only 2 missense changes in 6,500 indi-
viduals are in the SNF2 (sucrose non-fermentable 2)
domain (figure 4). Notably, 8 of 10 mutations re-
ported here cause premature truncation; only 2 cases
carry missense mutations and both lie within highly
conserved helicase domains. Therefore, the pheno-
type in patients with CHD2 encephalopathy is likely
due to haploinsufficiency of the CHD2 protein.
It is thought that CHD2 belongs to the SNF2-like
family of ATPase (adenosine triphosphatase) proteins
that have a role in chromatin remodeling and there-
fore may affect transcription of many genes. How-
ever, our knowledge of the function of CHD2,
particularly in the brain, is incomplete and warrants
further investigation to delineate its biological role.
Sodium valproate, one of the key antiepileptic drugs
for myoclonic and generalized epilepsies, inhibits his-
tone deacetylase activity and alters chromatin struc-
ture.19 Valproate was generally a favorable drug for
patients with CHD2 encephalopathy.
Knocked down chd2 zebrafish exhibit a seizure-
like phenotype as well as structural abnormalities of
microcephaly, body curvature, absent swim bladder,
and stunted growth.3 A murine Chd2 model con-
firmed that the CHD2 protein is widely expressed
during development in many tissues, although no
aberrations were noted in the brain.20
CHD2 mutations produce a distinctive myoclonic
epileptic encephalopathy with prominent clinical
photosensitivity in the majority of cases. The atonic-
myoclonic-absence seizures may prompt investigation
for a CHD2mutation. Recognition of CHD2 enceph-
alopathy will lead to improved diagnosis for patients
and families. Understanding the neurobiology of this
disorder will form the basis for the development of
genetically targeted therapies to improve outcome of
this severe epileptic encephalopathy.
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